[go: up one dir, main page]

CL2011001692A1 - Composicion farmaceutica que entrega acido butirico y glutamina directamente en el colon, para inducir la liberacion de una hormona intestinal desde celulas l del colon; su uso en diabetes tipo i o tipo ii y obesidad, entre otros. - Google Patents

Composicion farmaceutica que entrega acido butirico y glutamina directamente en el colon, para inducir la liberacion de una hormona intestinal desde celulas l del colon; su uso en diabetes tipo i o tipo ii y obesidad, entre otros.

Info

Publication number
CL2011001692A1
CL2011001692A1 CL2011001692A CL2011001692A CL2011001692A1 CL 2011001692 A1 CL2011001692 A1 CL 2011001692A1 CL 2011001692 A CL2011001692 A CL 2011001692A CL 2011001692 A CL2011001692 A CL 2011001692A CL 2011001692 A1 CL2011001692 A1 CL 2011001692A1
Authority
CL
Chile
Prior art keywords
colon
type
obesity
glutamine
diabetes
Prior art date
Application number
CL2011001692A
Other languages
English (en)
Inventor
Jerzy Ryszard Szewczyk
Original Assignee
Biokier Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biokier Inc filed Critical Biokier Inc
Publication of CL2011001692A1 publication Critical patent/CL2011001692A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Composición para inducir liberación de una hormona intestinal desde las células L en el colon, que comprende ácido butírico, un Ac. biliar, Ac. Graso de cadena larga y glutamina, formulada para que no se libere en estómago ni en tracto gi superior; y uso en el tratamiento y prevención de enfermedades tales como diabetes y obesidad.
CL2011001692A 2009-01-12 2011-07-11 Composicion farmaceutica que entrega acido butirico y glutamina directamente en el colon, para inducir la liberacion de una hormona intestinal desde celulas l del colon; su uso en diabetes tipo i o tipo ii y obesidad, entre otros. CL2011001692A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14395109P 2009-01-12 2009-01-12
US29377310P 2010-01-11 2010-01-11

Publications (1)

Publication Number Publication Date
CL2011001692A1 true CL2011001692A1 (es) 2012-04-13

Family

ID=42317190

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001692A CL2011001692A1 (es) 2009-01-12 2011-07-11 Composicion farmaceutica que entrega acido butirico y glutamina directamente en el colon, para inducir la liberacion de una hormona intestinal desde celulas l del colon; su uso en diabetes tipo i o tipo ii y obesidad, entre otros.

Country Status (23)

Country Link
US (2) US8470885B2 (es)
EP (1) EP2376077B1 (es)
JP (1) JP5702306B2 (es)
KR (4) KR20170034928A (es)
CN (1) CN102355896A (es)
AU (1) AU2010203413B2 (es)
BR (1) BRPI1006145B8 (es)
CA (1) CA2748827C (es)
CL (1) CL2011001692A1 (es)
CY (1) CY1119010T1 (es)
DK (1) DK2376077T3 (es)
EA (1) EA022631B1 (es)
ES (1) ES2628233T3 (es)
HR (1) HRP20170886T1 (es)
HU (1) HUE034551T2 (es)
LT (1) LT2376077T (es)
MX (1) MX2011007393A (es)
PL (1) PL2376077T3 (es)
PT (1) PT2376077T (es)
RS (1) RS56054B1 (es)
SI (1) SI2376077T1 (es)
SM (1) SMT201700278T1 (es)
WO (1) WO2010081079A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102316889B (zh) 2008-11-26 2014-11-26 萨蒂奥根制药公司 组合物及使用方法
US20220071895A1 (en) * 2009-01-12 2022-03-10 Biokier, Inc. Composition and method for treatment of diabetes
US20150224081A1 (en) * 2009-01-12 2015-08-13 Biokier, Inc. Composition and method for treatment of diabetes
WO2012161670A2 (en) 2010-04-07 2012-11-29 Incube Labs, Llc Method for treating diabetes and other glucose regulation disorders using stem cells
CN103429739B (zh) 2010-05-12 2018-11-13 哥伦比亚大学纽约管理委员会 制备产生和分泌胰岛素的肠内分泌细胞的方法
KR20140030171A (ko) * 2011-05-02 2014-03-11 바이오키어 인코포레이티드 당뇨병 치료를 위한 조성물 및 치료법
KR20130055220A (ko) 2011-11-18 2013-05-28 삼성전자주식회사 동박적층판 및 이를 사용한 금속코어기판의 제조방법
CN108478551A (zh) * 2011-11-21 2018-09-04 埃默斯医疗股份有限公司 用于治疗糖尿病和相关病症的方法和组合物
US20150073057A1 (en) * 2013-09-06 2015-03-12 Biokier, Inc. Composition and method for treatment of diabetes
CA2985344A1 (en) 2014-06-26 2015-12-30 The Trustees Of Columbia University In The City Of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
EP4194001A1 (en) * 2015-04-22 2023-06-14 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes and obesity
US11291693B2 (en) 2015-06-25 2022-04-05 Synlogic Operating Company, Inc. Bacteria engineered to treat metabolic diseases
US9668991B1 (en) 2015-12-09 2017-06-06 International Business Machines Corporation SCFA colonic composition
CN107684550B (zh) * 2016-08-03 2020-04-10 徐天宏 糖尿病治疗产品及其制备与应用
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US20210084956A1 (en) 2018-02-23 2021-03-25 Ambra Bioscience Llc Compositions and methods for hunger control and weight management
WO2019246225A1 (en) 2018-06-20 2019-12-26 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
KR20220046623A (ko) 2019-08-12 2022-04-14 메사추세츠 인스티튜트 오브 테크놀로지 치료제의 투여를 위한 물품 및 방법
US20230190686A1 (en) * 2021-12-17 2023-06-22 Biokier, Inc. Composition and method for treatment of diabetes

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA885473B (en) * 1987-08-07 1989-03-29 Century Lab Inc Free fatty acids for treatment of diabetes mellitus
IT1245890B (it) * 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
WO1999007342A1 (en) 1997-08-11 1999-02-18 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
US6652882B1 (en) 1997-10-06 2003-11-25 Intellipharmaceutics Corp Controlled release formulation containing bupropion
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
IL142650A (en) 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
DK1183014T3 (da) 1999-06-14 2004-02-09 Cosmo Spa Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
EP1364957B1 (en) 2001-02-26 2008-12-31 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
US20030203004A1 (en) * 2002-04-24 2003-10-30 Kelm Gary Robert Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
DE60300502T2 (de) 2003-10-28 2006-02-23 Adorkem Technology S.P.A., Costa Volpino Verfahren zur Herstellung von Citalopram
ITMI20040187A1 (it) 2004-02-06 2004-05-06 Cosmo Spa Composizioni farmaceutiche o dietetiche a base di acidi grassi a catena corta e zuccheri complessi per le disfunzioni intestinali
ITMI20041295A1 (it) 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
JP2006056881A (ja) 2004-07-21 2006-03-02 Takeda Chem Ind Ltd 縮合環化合物
JP2006063064A (ja) 2004-07-27 2006-03-09 Takeda Chem Ind Ltd 受容体作動剤
AU2006250354A1 (en) 2005-05-23 2006-11-30 Japan Tobacco Inc. Pyrazole compound and therapeutic agent for diabetes comprising the same
DE102005046237A1 (de) * 2005-09-28 2007-04-05 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Buttersäureester von Kohlenhydraten und Kohlenhydratpolyolen
ITMI20052000A1 (it) * 2005-10-21 2007-04-22 Promefarm S R L Compressa gastroresitente a base di butirrato di sodio
CN101404987A (zh) 2006-01-20 2009-04-08 史密丝克莱恩比彻姆公司 磺酰胺衍生物在治疗代射和神经系统疾病中的用途
US20090035306A1 (en) 2006-11-29 2009-02-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
CA2673054C (en) * 2006-12-15 2016-05-10 Tima Foundation Novel compositions and uses thereof
WO2010062861A2 (en) 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
CN102316889B (zh) 2008-11-26 2014-11-26 萨蒂奥根制药公司 组合物及使用方法
BRPI1007518A2 (pt) 2009-02-10 2018-02-20 Amarin Pharma, Inc. uso de acido etil ester eicopentanoico para tratamento de hipertrigliceridemia
AU2010260129B2 (en) 2009-06-15 2014-05-29 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels
BR112012006692B8 (pt) 2009-09-23 2021-05-25 Amarin Corp Plc composição farmacêutica compreendendo um derivado de hidróxi de atorvastatina e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato

Also Published As

Publication number Publication date
KR20190062609A (ko) 2019-06-05
JP5702306B2 (ja) 2015-04-15
EP2376077B1 (en) 2017-03-15
EA201190068A1 (ru) 2012-01-30
SI2376077T1 (sl) 2017-09-29
EA022631B1 (ru) 2016-02-29
CA2748827C (en) 2017-10-10
US8470885B2 (en) 2013-06-25
JP2012515163A (ja) 2012-07-05
WO2010081079A3 (en) 2010-11-25
CN102355896A (zh) 2012-02-15
WO2010081079A2 (en) 2010-07-15
DK2376077T3 (en) 2017-06-26
HRP20170886T1 (hr) 2017-09-08
AU2010203413A1 (en) 2011-07-14
BRPI1006145B8 (pt) 2021-05-25
BRPI1006145A2 (pt) 2017-05-30
AU2010203413B2 (en) 2015-05-14
EP2376077A2 (en) 2011-10-19
LT2376077T (lt) 2017-08-10
RS56054B1 (sr) 2017-09-29
KR20110120866A (ko) 2011-11-04
KR20170034928A (ko) 2017-03-29
PL2376077T3 (pl) 2017-10-31
ES2628233T3 (es) 2017-08-02
US8680085B2 (en) 2014-03-25
MX2011007393A (es) 2011-10-06
BRPI1006145B1 (pt) 2021-03-09
US20110275716A1 (en) 2011-11-10
EP2376077A4 (en) 2012-08-29
CA2748827A1 (en) 2010-07-15
US20130102581A1 (en) 2013-04-25
KR20170138573A (ko) 2017-12-15
SMT201700278T1 (it) 2017-07-18
HUE034551T2 (en) 2018-02-28
CY1119010T1 (el) 2018-01-10
PT2376077T (pt) 2017-06-23

Similar Documents

Publication Publication Date Title
CL2011001692A1 (es) Composicion farmaceutica que entrega acido butirico y glutamina directamente en el colon, para inducir la liberacion de una hormona intestinal desde celulas l del colon; su uso en diabetes tipo i o tipo ii y obesidad, entre otros.
GT200600297A (es) Nuevos anticuerpos anti-madcam
MX337575B (es) Compuestos de sulfona y métodos para lafabricación y uso de éstos.
EA201490982A1 (ru) Аналоги глюкагона
CO6511276A2 (es) Composición probiótica para uso en el tratamiento de la inflamación del intestino
CY1119596T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
HN2011003218A (es) Peptidos especificos para receptores de melanocortina
CL2011000099A1 (es) Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria.
AR091422A1 (es) Analogos peptidicos de la exendina 4
CR20110255A (es) Nuevos compuestos 578
CR20110509A (es) Composicion farmaceutica
CL2009000120A1 (es) Compuestos derivados de carboxamidas n-aza-biciclicas; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso como antagonistas o agonistas del receptor tipo trpv1 para tratar el dolor, la inflamacion, trastornos metabolicos, urologicos, ginecologicos, gastrointestinales, respiratorios.
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
MX382408B (es) Coagonistas de los receptores de glucagón y de glp-1.
MX385777B (es) Derivado de biarilo como agonista de gpr120.
CL2012003226A1 (es) Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas.
HN2012001321A (es) Analogo peptidico de oxintomodulina
CL2012000794A1 (es) Composicion farmaceutica solida de desintegracion oral que comprende 20 mg o menos de un un corticoesteroide y un desintegrador; tableta que se desintegra oralmente; y su uso en el tratamiento de una afeccion inflamatoria del tracto gastrointestinal como inflamacion del esofago, glosis, epiglotis, amigdalas, orofaringea, entre otras.
CO6430487A2 (es) Anticuerpos anti-her
CL2012000738A1 (es) Compuestos heterociclicos derivados de indol, inhibidores de xantina-oxidasa; composición farmacéutica que los comprende; procedimiento de preparación; y uso en el tratamiento de enfermedades tales como hiperuricemia, gota, insuficiencia cardiaca, hipertensión, diabetes, hiperlipidemia, obesidad, aterosclerosis, entre otras.
DOP2012000246A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
UY32393A (es) Dicianopiridinas alquilamino-sustituidas y sus profarmacos de ester de aminoacido
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
MX2012003459A (es) Composicion y metodo para el tratamiento de la diabetes.
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119